281 related articles for article (PubMed ID: 23354028)
61. Implication of lymph node metastasis detected on 18F-FDG PET/CT for surgical planning in patients with peripheral intrahepatic cholangiocarcinoma.
Park TG; Yu YD; Park BJ; Cheon GJ; Oh SY; Kim DS; Choe JG
Clin Nucl Med; 2014 Jan; 39(1):1-7. PubMed ID: 24335565
[TBL] [Abstract][Full Text] [Related]
62. Differentiation of malignant and benign cardiac tumors using 18F-FDG PET/CT.
Rahbar K; Seifarth H; Schäfers M; Stegger L; Hoffmeier A; Spieker T; Tiemann K; Maintz D; Scheld HH; Schober O; Weckesser M
J Nucl Med; 2012 Jun; 53(6):856-63. PubMed ID: 22577239
[TBL] [Abstract][Full Text] [Related]
63. [Diagnostic value of (18)F-FDG PET/CT imaging plus serum tumor marker assays for pulmonary lesions and clinical significance of SUVmax].
Zhang TM; Zhang LM; Liu Y; Zhang ZF; Wang CL
Zhonghua Yi Xue Za Zhi; 2012 Nov; 92(41):2901-4. PubMed ID: 23328236
[TBL] [Abstract][Full Text] [Related]
64. Metabolic Activity by 18F-FDG-PET/CT Is Prognostic for Stage I and II Pancreatic Cancer.
Pimiento JM; Davis-Yadley AH; Kim RD; Chen DT; Eikman EA; Berman CG; Malafa MP
Clin Nucl Med; 2016 Mar; 41(3):177-81. PubMed ID: 26673243
[TBL] [Abstract][Full Text] [Related]
65. CT, MRI, and FDG PET/CT in a patient with alveolar soft part sarcoma.
Dong A; Wang Y; Cheng C; Zuo C
Clin Nucl Med; 2014 Mar; 39(3):265-7. PubMed ID: 23856828
[TBL] [Abstract][Full Text] [Related]
66. Preliminary evaluation of 18F-FDG-PET/MRI for differentiation of serous from nonserous pancreatic cystic neoplasms: a pilot study.
Sagheb S; Metser U; Razaz S; Menezes R; Gallinger S; Jhaveri KS
Nucl Med Commun; 2020 Dec; 41(12):1257-1264. PubMed ID: 32925829
[TBL] [Abstract][Full Text] [Related]
67. 18F-FDG PET/MR in an Atypical Pediatric Solid Pseudopapillary Pancreatic Tumor.
Cavaliere A; Giraudo C; Zuliani M; Cecchin D; Quaia E
Clin Nucl Med; 2019 Sep; 44(9):e522-e523. PubMed ID: 31274565
[TBL] [Abstract][Full Text] [Related]
68. Alveolar echinococcosis: correlation between hepatic MRI findings and FDG-PET/CT metabolic activity.
Azizi A; Blagosklonov O; Lounis A; Berthet L; Vuitton DA; Bresson-Hadni S; Delabrousse E
Abdom Imaging; 2015 Jan; 40(1):56-63. PubMed ID: 24970734
[TBL] [Abstract][Full Text] [Related]
69. Incidental diagnosis of tumor thrombosis on FDG PET/CT imaging.
Erhamamci S; Reyhan M; Nursal GN; Torun N; Yapar AF
Rev Esp Med Nucl Imagen Mol; 2015; 34(5):287-94. PubMed ID: 26025479
[TBL] [Abstract][Full Text] [Related]
70. [CT imaging features and their correlation with pathological findings of solid pseudopapillary tumor of pancreas].
Zheng X; Tan X; Wu B
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2014 Feb; 31(1):107-12. PubMed ID: 24804494
[TBL] [Abstract][Full Text] [Related]
71. CT, MRI, and
Wu M; Lin J; Liu Z; Huang Z; Wang R
BMC Med Imaging; 2022 Dec; 22(1):228. PubMed ID: 36581821
[TBL] [Abstract][Full Text] [Related]
72. Tumor thrombus: ancillary findings on FDG PET/CT in an oncologic population.
Ravina M; Hess S; Chauhan MS; Jacob MJ; Alavi A
Clin Nucl Med; 2014 Sep; 39(9):767-71. PubMed ID: 24999677
[TBL] [Abstract][Full Text] [Related]
73. ¹⁸F-FDG PET/CT in HIV-related central nervous system pathology.
Lewitschnig S; Gedela K; Toby M; Kulasegaram R; Nelson M; O'Doherty M; Cook GJ
Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1420-7. PubMed ID: 23685752
[TBL] [Abstract][Full Text] [Related]
74. (18)F-FDG PET/CT in differentiating acute tuberculous from idiopathic pericarditis: preliminary study.
Dong A; Dong H; Wang Y; Cheng C; Zuo C; Lu J
Clin Nucl Med; 2013 Apr; 38(4):e160-5. PubMed ID: 23429393
[TBL] [Abstract][Full Text] [Related]
75. 18F-FDG activitiy PET/CT and CA-19.9 levels for the prediction of histopathological features and localization of peri- ampullary tumors.
Akcam AT; Ülkü A; Rencuzoğulları A; Parsak CK; Yapar Z; Doran F; Demiryürek H; Okoh AK
Turk J Gastroenterol; 2015 Mar; 26(2):170-5. PubMed ID: 25835117
[TBL] [Abstract][Full Text] [Related]
76.
Zhang J; Jia G; Zuo C; Jia N; Wang H
BMC Cancer; 2017 Oct; 17(1):695. PubMed ID: 29061130
[TBL] [Abstract][Full Text] [Related]
77. Tumor aggressiveness and patient outcome in cancer of the pancreas assessed by dynamic 18F-FDG PET/CT.
Epelbaum R; Frenkel A; Haddad R; Sikorski N; Strauss LG; Israel O; Dimitrakopoulou-Strauss A
J Nucl Med; 2013 Jan; 54(1):12-8. PubMed ID: 23166388
[TBL] [Abstract][Full Text] [Related]
78. Limited efficacy of (18)F-FDG PET/CT for differentiation between metastasis-free pancreatic cancer and mass-forming pancreatitis.
Kato K; Nihashi T; Ikeda M; Abe S; Iwano S; Itoh S; Shimamoto K; Naganawa S
Clin Nucl Med; 2013 Jun; 38(6):417-21. PubMed ID: 23486318
[TBL] [Abstract][Full Text] [Related]
79. MRI, enhanced CT, and FDG PET/CT in primary retroperitoneal mucinous cystadenocarcinoma.
Dong A; Zhai Z; Wang Y; Zuo C
Clin Nucl Med; 2015 Jan; 40(1):50-3. PubMed ID: 24445275
[TBL] [Abstract][Full Text] [Related]
80. CT target scanning in the diagnosis of solid pseudopapillary tumor of the pancreas.
Wang HT; Wang YT; Yu ZH; Tu C; Lu B; Yu L; Feng D; Wang TG
BMC Med Imaging; 2023 Dec; 23(1):214. PubMed ID: 38102549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
